Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-benzyl-2-hydroxy-2-(4-hydroxy-benzyl)-6-(4-hydroxyphenyl)-2h-imidazo[1,2-a]pyrazin‑3‑one is a synthetic small molecule belonging to the imidazopyrazinone class. It has a molecular formula of C26H21N3O4 and an average mass of approximately 439.47 g/mol. The compound is structurally related to coelenterazine analogs and features multiple hydroxybenzene moieties attached to an imidazopyrazine core. While its precise mechanism of action and pharmacological activity are not fully characterized in public databases, it is described as having potential biological activities and is classified as experimental in drug research resources. There are no approved therapeutic indications or marketed products containing this compound at this time[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-benzyl-2-hydroxy-2-(4-hydroxy-benzyl)-6-(4-hydroxy-phenyl)-2h-imidazo[1,2-a]pyrazin-3-one.